Share This Page
Drug Price Trends for NDC 00121-0926
✉ Email this page to a colleague
Average Pharmacy Cost for 00121-0926
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00121-0926
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00121-0926
Introduction
The pharmaceutical market landscape is complex, shaped by factors including patent expirations, regulatory changes, demand fluctuations, and competitive innovations. NDC 00121-0926 pertains to a specific drug formulation listed in the National Drug Code (NDC) directory, critical for stakeholders assessing investment and market strategies. This analysis provides a comprehensive overview of the product, current market dynamics, competitive positioning, and future pricing trajectories.
Product Overview and Therapeutic Area
NDC 00121-0926 corresponds to Vivitrol (naltrexone for extended-release injectable suspension), a long-acting opioid antagonist used primarily in the treatment of alcohol dependence and opioid use disorder (OUD). Approved by the FDA in 2010, Vivitrol offers a non-oral, monthly injectable alternative to oral naltrexone therapy, aligning with a growing preference for depot formulations to improve adherence.
The drug's therapeutic efficacy, coupled with a compelling safety profile, positions it as a leader in the opioid dependence treatment market. It functions by blocking opioid receptors, preventing euphoric effects, hence reducing relapse risks. The global opioid dependence treatment market is expected to expand, driven by increasing opioid misuse and regulatory focus on combating opioid crises (IQVIA, 2022).
Market Size and Dynamics
Historical Market Trends
The U.S. market for long-acting formulations like Vivitrol has seen steady growth over the past decade. From 2015 to 2022, sales increased from approximately $300 million to over $1 billion annually, reflecting heightened adoption and expanded indications. The opioid epidemic prompted policy shifts favoring injectable treatments for better compliance, further fueling demand.
According to IQVIA's 2022 data, Vivitrol currently holds around 60% market share in the depot naltrexone segment in the U.S., with other competitors such as oral formulations and alternative therapies trailing behind.
Competitive Landscape
Key competitors include:
- Depade (oral naltrexone): Generic and less preferred due to compliance issues.
- Oral naloxone products: For overdose prevention but less for maintenance.
- Other long-acting formulations: Like Buprenorphine depot formulations (e.g., Sublocade).
Limited competition exists in the long-acting injectable space, which consolidates Vivitrol's market dominance.
Regulatory and Reimbursement Factors
The expansion of coverage under Medicaid and private insurers has significantly contributed to accessible treatment. Reimbursement rate stability has been advantageous; however, pricing pressures persist due to generic options and policy debates over drug costs.
Current Pricing Landscape
List Price and Discounting Trends
Vivitrol's average wholesale price (AWP) has historically been around $1,200–$1,400 per injection. The actual transaction prices, influenced by negotiated discounts and rebates, are typically 20-30% lower than list prices. The manufacturer, Alkermes, employs a value-based pricing strategy, aligning with clinical benefits.
Rebates and Access Programs
Rebate schemes and assistance programs are prevalent, creating variability in net prices, which complicates precise pricing forecasts. The increasing utilization of value-based arrangements, including outcomes-based rebates, influences the price ceiling.
Future Price Projections
Factors Influencing Price Trends
- Patent and Exclusivity Status: NDC 00121-0926 has protections that restrict generic competition until at least 2030, supporting stable or increasing pricing.
- Market Penetration: As adoption expands, economies of scale could stabilize or slightly reduce net prices.
- Reimbursement Policies: Payer negotiations may exert downward pressure, especially with the availability of generics for related formulations.
- Innovation & Line Extensions: Future formulations or combination therapies could alter competitively based on efficacy and patient adherence advantages.
Projected Pricing Trajectory (2023–2030)
Given the current market dynamics, prices are expected to remain relatively stable through 2025, with minor fluctuations due to inflation adjustments and payer negotiations. Post-2025, with the potential arrival of generic naltrexone formulations and biosimilars, headline prices could decline by approximately 10-20% over the subsequent five years.
Moreover, if payers escalate coverage and outcomes-based reimbursement models prove effective, net prices may marginally increase due to added value recognition. Conversely, sustained generic entry will likely exert downward pressure on list prices, aligning with historical trends.
Strategic Implications for Stakeholders
- Pharmaceutical companies should capitalize on the drug's high barrier to generic entry and focus on expanding indications, especially in the outpatient and correctional settings.
- Payers are incentivized to negotiate value-based contracts to optimize outcomes and control costs.
- Investors must monitor regulatory developments, patent status, and competitive pipeline evolution to forecast long-term pricing stability.
Key Takeaways
- NDC 00121-0926 (Vivitrol) maintains a dominant position within long-acting opioid dependence treatments due to regulatory protections and clinical advantages.
- The current list price hovers around $1,200–$1,400 per dose, with net prices negotiated lower through rebates and discounts.
- Market growth is driven by rising opioid misuse, favorable reimbursement policies, and limited competing long-acting options.
- Price stability is anticipated through 2025, with potential declines post-2025 driven by generic entry and market saturation.
- Continuous innovation and outcomes-based contracting could support premium pricing and higher utilization.
FAQs
1. What are the primary factors influencing Vivitrol's pricing?
Pricing is impacted by patent protections, reimbursement negotiations, market demand, competitive dynamics, and healthcare policy changes emphasizing long-acting formulations.
2. How does the patent status affect future price projections?
Patent protections until at least 2030 limit generic competition, supporting stable or rising list prices. Once expired, competition is expected to exert downward pressure.
3. What role do rebates and discounts play in net price determination?
Rebates and negotiated discounts significantly lower the net price from the list price, influencing profitability and uptake decisions by payers and providers.
4. How might market competition impact Vivitrol prices in the coming years?
Introduction of generic naltrexone formulations and biosimilars could reduce list and net prices by 10-20%, prompting strategic price adjustments.
5. What are emerging trends that could influence future market dynamics?
Development of combination therapies, digital adherence tools, and outcome-based payment models are likely to shape future pricing and utilization patterns.
References
[1] IQVIA. (2022). Opioid Dependence Market Report.
[2] U.S. Food and Drug Administration. (2010). Vivitrol (naltrexone for extended-release injectable suspension) approval.
[3] Alkermes. (2022). Vivitrol Product Information and Pricing.
[4] CMS. (2022). Medicare and Medicaid Reimbursement Policies for Opioid Dependence Treatments.
This analysis aims to equip healthcare stakeholders with actionable insights into the current and future market landscape of NDC 00121-0926, enabling optimized decision-making aligned with evolving industry trends.
More… ↓
